Sartorius to Acquire TAP Biosystems
According to a regulatory filing, for the year ending April 5, 2013, TAP revenues grew 8.5% to £21.8 million ($34.1 million = €0.64 = $1). Sales of cell culture products and consumables increased 16% to make up 62% of revenues, as shipments of the ambr single-use fermentation systems grew 41%. As part of the filing, Sartorius stated that TAP’s automated cell culture products complement its small-scale bioreactor products.
Aubagne, France 10/7/13—Sartorius Stedim Biotech has made a cash offer to acquire UK-based TAP Biosystems. The offer values the equity of TAP at approximately €33 million ($45 million = €0.74 = $1). TAP designs and develops small scale, multi-parallel fermentation systems, automated cell processing systems and other benchtop equipment. “Adding capabilities in the early steps of upstream bioprocessing will enable us to provide our biopharma customers highly effective and scalable solutions to accelerate cell line selection, speed-up process development and ultimately help them in bringing their biologics to market faster,” stated Sartorius Stedim Biotech Chief Executive Joachim Kreuzburg. All TAP employees will join Sartorius. The acquisition is expected to close by year end.
